Abundance Wealth Counselors Has $711,000 Stock Position in GSK plc (NYSE:GSK)

Abundance Wealth Counselors lessened its stake in GSK plc (NYSE:GSK) by 6.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,011 shares of the pharmaceutical company’s stock after selling 1,404 shares during the quarter. Abundance Wealth Counselors’ holdings in GSK were worth $711,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Eastern Bank acquired a new position in GSK in the 3rd quarter worth $26,000. Crews Bank & Trust acquired a new position in shares of GSK during the fourth quarter worth about $26,000. ST Germain D J Co. Inc. grew its holdings in shares of GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 522 shares in the last quarter. Sunbelt Securities Inc. raised its position in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 302 shares during the last quarter. Finally, Concord Wealth Partners lifted its stake in GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 547 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Trading Down 0.4 %

Shares of NYSE:GSK opened at $35.20 on Friday. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The company has a market capitalization of $72.96 billion, a P/E ratio of 22.86, a price-to-earnings-growth ratio of 1.37 and a beta of 0.63. The company has a 50-day simple moving average of $34.07 and a 200 day simple moving average of $37.69.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on GSK shares. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Finally, Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and dropped their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Six equities research analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.